Top Stories11 hours ago
Edesa Biotech Announces Breakthrough Results in ARDS Study
UPDATE: Edesa Biotech, Inc. (Nasdaq: EDSA) has just announced groundbreaking results from its Phase 3 study of paridiprubart (EB05) for treating Acute Respiratory Distress Syndrome (ARDS)....